Loading...
Loading...
- Arbutus Biopharma Corp ABUS reported Q1 2023 revenues of $6.7 million, beating the consensus of $6.02 million.
- Revenues declined from $12.6 million in the prior year owing to lower revenue recognition from the license agreement with Qilu.
- Research and development expenses declined to $18.3 million from $18.5 million a year ago due to reduced costs for AB-836 Phase 1a/1b clinical trial on discontinuation in Q4 2022.
- The company reported a loss per share of $(0.10), better than the consensus estimate of $(0.14).
- As of March 31, 2023, cash, cash equivalents and investments in marketable securities stood at $178.5 million.
- In April, AB-101 IND was placed on hold by the FDA and the company will not report initial data from the single-ascending dose portion of a Phase 1 clinical trial in H2 2023. Consequently, ABUS reduced 2023 cash burn guidance to $90-$95 million from $95-$100 million earlier.
- "In the first quarter of 2023, we made meaningful progress advancing our pipeline of HBV and coronavirus assets to address large global market opportunities. We reported data from our lead HBV-focused RNAi therapeutic, AB-729, showing low levels of HBsAg and HBV DNA in most patients persisting for at least a year and a half after their last dose of AB-729," said William Collier, Arbutus' President and CEO.
- He added, "In addition, we dosed the first healthy subject in our Phase 1 clinical trial with AB-161, our oral RNA destabilizer, for which we expect data in the second half of this year. We continue to advance our coronavirus programs and expect to initiate a Phase 1 clinical trial with our Mpro inhibitor candidate, AB-343, as well as IND-enabling studies for an nsp12 inhibitor candidate in the second half of this year."
- Price Action: ABUS shares are trading higher by 1.79% at $2.55 on the last check Thursday.
Loading...
Loading...
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Date | ticker | name | Actual EPS | EPS Surprise | Actual Rev | Rev Surprise |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in